As of 2025-07-19, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -5.71 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 32.01 USD, the upside of Viking Therapeutics Inc is -117.84%.
Based on its market price of 32.01 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 117.84%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.71 - -5.71 | -5.71 | -117.84% |
| P/E | (19.71) - (27.36) | (24.41) | -176.2% |
| DDM - Stable | (7.74) - (28.34) | (18.04) | -156.4% |
| DDM - Multi | (0.19) - (0.55) | (0.29) | -100.9% |
| Market Cap (mil) | 3,595.04 |
| Beta | 1.31 |
| Outstanding shares (mil) | 112.31 |
| Enterprise Value (mil) | 3,557.10 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.98% |
| Cost of Debt | 5.00% |
| WACC | 7.32% |